Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8359063 | 0.87 | MEN1 (0.44) | KMT2AMEN1POLBCYP2D6LMNA | |
| SCHEMBL4184981 | 0.86 | KDM4E (0.37) | KMT2AMEN1POLBHTR3AHRH3 | |
| SCHEMBL5536881 | 0.84 | ALDH1A1 (0.40) | KMT2AMEN1CYP2D6MAOAALDH1A1 | |
| SCHEMBL5538653 | 0.82 | ALDH1A1 (0.42) | KMT2AMEN1CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL5540330 | 0.82 | ALDH1A1 (0.42) | KMT2AMEN1CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL5535421 | 0.82 | ALDH1A1 (0.42) | KMT2AMEN1CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL5547136 | 0.82 | ALDH1A1 (0.42) | KMT2AMEN1CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL5548088 | 0.82 | ALDH1A1 (0.42) | KMT2AMEN1CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL5546030 | 0.82 | ALDH1A1 (0.42) | KMT2AMEN1CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL5545245 | 0.82 | ALDH1A1 (0.42) | KMT2AMEN1CYP2D6ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165474-A1 | POLYFARNESENES | Amyris, Inc. (US) | 2012-06-28 | — | — | US | claimed |
| EP-1278735-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | claimed |
| US-7067522-B2 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | claimed |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB | 2005-04-28 | — | — | US | claimed |
| US-6838464-B2 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | claimed |
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | US | claimed |
| EP-1278735-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2001064656-A1 | 2,4,DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | claimed |
| EP-0173933-B1 | 1,6-NAPHTHYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENT CONTAINING THEM | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-11-29 | — | — | EP | claimed |
| US-4525478-A | Certain 4-aryl-1,4-dihydro-3,5-pyridinedicarboxylates having vasodilating and anti-hypertensive properties | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-25 | — | — | US | claimed |
| US-4370334-A | VASODILATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-01-25 | — | — | US | claimed |
| US-4338322-A | 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-07-06 | — | — | US | claimed |
| US-4284634-A | HYPOTENSIVE VASODILATORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-08-18 | — | — | US | claimed |
| US-4159330-A | ANTIALLERGENS | CARLO ERBA S.P.A. (IT) | 1979-06-26 | — | — | US | claimed |
| EP-2817342-B1 | POLYMERIZATION OF COMPOSITIONS COMPRISING A FARNESENE | AMYRIS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20150025193-A1 | POLYMERIZATION OF COMPOSITIONS COMPRISING A FARNESENE | Amyris, Inc. (US) | 2015-01-22 | — | — | US | disclosed |
| EP-2817342-A1 | POLYMERIZATION OF COMPOSITIONS COMPRISING A FARNESENE | Amyris, Inc. (US) | 2014-12-31 | — | — | EP | disclosed |
| US-4303673-A | N-Propionylsarcosineanilides, process for their preparation, and pharmaceutical compositions containing them | A. NATTERMANN & CIE. GMBH (DE) | 1981-12-01 | — | — | US | disclosed |
| US-4297358-A | AS ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1981-10-27 | — | — | US | disclosed |
| US-4159330-A | ANTIALLERGENS | CARLO ERBA S.P.A. (IT) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | KMT2A 909/4885MEN1 3683/4885POLB 254/4885 |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | CDK2, CDK4, CCNI | KMT2A 862/4885MEN1 4075/4885POLB 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.